<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The risk of a newly diagnosed episode of upper <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> liver and <z:hpo ids='HP_0000083'>renal failure</z:hpo>, <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, severe <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disorders</z:e>, and <z:mp ids='MP_0002531'>anaphylaxis</z:mp> was examined within 30 days after the first prescription for a low dose of <z:chebi fb="0" ids="47381">diclofenac</z:chebi>, naproxen, or <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> in a cohort in the United Kingdom </plain></SENT>
<SENT sid="1" pm="."><plain>We identified 22,146 persons using <z:chebi fb="0" ids="47381">diclofenac</z:chebi> (&lt; or = 75 mg), 46,919 using naproxen (&lt; or = 750 mg), and 54,830 using <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> (&lt; or = 1200 mg) </plain></SENT>
<SENT sid="2" pm="."><plain>Age, gender, and comorbidity were similar in the three cohorts </plain></SENT>
<SENT sid="3" pm="."><plain>Overall 64 potential cases were identified, and 20 were confirmed by medical record review </plain></SENT>
<SENT sid="4" pm="."><plain>Incidence rates (95% CI) of upper <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo>/10,000 people using <z:chebi fb="0" ids="47381">diclofenac</z:chebi>, naproxen, and <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> were 1.8 (0.5-4.6), 2.3 (1.2-4.2), and 0.4 (0.04-1.3), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>There were three cases of hepatic injury, one with naproxen and two with <z:chebi fb="1" ids="5855">ibuprofen</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Although low, the incidence of gastrointestinal toxicity remains the main serious adverse event for <z:hpo ids='HP_0000001'>all</z:hpo> study drugs </plain></SENT>
</text></document>